Immunic Inc. (IMUX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022 6:30 AM EDTInitial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter
Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Expected in the Third Quarter
$88.1 Million in Cash and Cash Equivalents Expected to Fund Immunic Into the Fourth Quarter of 2023
Webcast to be Held Today, August 4, 2022, at 8:00 am ET
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq:... More
